|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
ES2017924B3
(es)
|
1985-10-11 |
1991-03-16 |
Duphar Int Res B V |
Inyector automatico.
|
|
GB2209937B
(en)
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
|
US5981485A
(en)
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
HU221294B1
(en)
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5578442A
(en)
|
1992-03-23 |
1996-11-26 |
Vivorx, Inc. |
Graft copolymers of polycationic species and water-soluble polymers, and use therefor
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US5643605A
(en)
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5858964A
(en)
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
IT1276690B1
(it)
|
1995-06-09 |
1997-11-03 |
Ira Srl |
Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
|
|
NZ325561A
(en)
|
1996-01-24 |
1999-06-29 |
Us Army |
Pharmaceutical composition containing an active ingredient and poly(lactide/glycolide) microcapsules which is a burst free controlled release formulation
|
|
BRPI9707379C8
(pt)
|
1996-02-09 |
2017-12-12 |
Abbott Biotech Ltd |
composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
|
|
US5792477A
(en)
|
1996-05-07 |
1998-08-11 |
Alkermes Controlled Therapeutics, Inc. Ii |
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
|
|
US20070185032A1
(en)
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
US5945126A
(en)
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
|
AR012448A1
(es)
|
1997-04-18 |
2000-10-18 |
Ipsen Pharma Biotech |
Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
|
|
US6454746B1
(en)
|
1997-06-04 |
2002-09-24 |
Eli Lilly And Company |
Medication delivery apparatus
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
JP2002503658A
(ja)
|
1998-02-13 |
2002-02-05 |
オートイミューン インク |
COP−1及びTh−2促進性サイトカインを使用した、多発性硬化症の治療
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
DE09004306T1
(de)
|
1998-09-25 |
2010-12-09 |
Yeda Research & Development Co., Ltd., Weizmann Institute of Science |
Mit Copolymer 1 verwandte Polypeptide zur Verwendung als Molekulargewichtsmarker und zur therapeutischen Verwendung
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000020010A1
(en)
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
WO2000027417A1
(en)
|
1998-11-12 |
2000-05-18 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
|
|
US6194006B1
(en)
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
|
US6872739B1
(en)
|
1999-06-04 |
2005-03-29 |
Vereniging Voor Christelijk Wetenshappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
US6531130B1
(en)
|
1999-07-06 |
2003-03-11 |
The Board Of Trustees Of The Leland Stanford University |
Treatment of demyelinating autoimmune disease with ordered peptides
|
|
EP1248643B1
(en)
|
2000-01-20 |
2005-08-17 |
YEDA RESEARCH AND DEVELOPMENT Co. LTD. |
The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
|
|
CA2400374A1
(en)
|
2000-02-18 |
2001-08-23 |
Adrian Gilbert |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
CA2411536A1
(en)
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
EP1294390B1
(en)
|
2000-06-07 |
2006-01-04 |
YEDA RESEARCH AND DEVELOPMENT CO., Ltd. |
The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
KR100392501B1
(ko)
|
2000-06-28 |
2003-07-22 |
동국제약 주식회사 |
다중 에멀젼법에 의한 서방출성 미립구의 제조방법
|
|
US8658627B2
(en)
|
2001-04-25 |
2014-02-25 |
The Regents Of The University Of California |
Pregnancy hormone combination for treatment of autoimmune diseases
|
|
US6835711B2
(en)
|
2001-06-28 |
2004-12-28 |
Yeda Research And Development Co. Ltd. |
Use of poly-Glu,Tyr for neuroprotective therapy
|
|
EA005537B1
(ru)
|
2001-07-10 |
2005-04-28 |
Тева Фармасьютикал Индастриес Лтд. |
Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
|
|
HUP0401863A3
(en)
|
2001-10-03 |
2012-09-28 |
Harvard College |
Amino acid-copolymers for suppression of autoimmune diseases, and methods of use
|
|
WO2003030902A1
(en)
|
2001-10-09 |
2003-04-17 |
Tularik Inc. |
Imidazole derivates as anti-inflammatory agents
|
|
WO2003048207A2
(en)
|
2001-11-28 |
2003-06-12 |
Immunomedics, Inc. |
Anti-dota antibody
|
|
CN1308683C
(zh)
|
2001-12-04 |
2007-04-04 |
特瓦制药工业有限公司 |
测量醋酸格拉默功效的方法
|
|
EP1429800B1
(en)
|
2001-12-06 |
2009-02-11 |
Yeda Research And Development Co., Ltd. |
Vaccine and use thereof for treatment of amyotrophic lateral sclerosis
|
|
US8871241B2
(en)
|
2002-05-07 |
2014-10-28 |
Psivida Us, Inc. |
Injectable sustained release delivery devices
|
|
CN1398584A
(zh)
|
2002-07-15 |
2003-02-26 |
裴福兴 |
一种bFGF-PLGA缓释微球及其制备方法和用途
|
|
DE10237146A1
(de)
|
2002-08-13 |
2004-03-04 |
Medac Gesellschaft für klinische Spezialpräparate mbH |
Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
|
|
EP1556053A4
(en)
|
2002-10-31 |
2006-04-19 |
Amgen Inc |
ANTI-INFLAMMATORY AGENTS
|
|
WO2004043995A2
(en)
|
2002-11-13 |
2004-05-27 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
AU2003275895B2
(en)
|
2002-11-25 |
2009-02-05 |
Tecpharma Licensing Ag |
Auto-injector comprising a resettable releasing safety device
|
|
AU2004203772B2
(en)
|
2003-01-07 |
2009-07-16 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
|
ES2397836T3
(es)
|
2003-01-21 |
2013-03-11 |
Yeda Research And Development Co., Ltd. |
Copolímero 1 para el tratamiento de enfermedades inflamatorias del intestino
|
|
WO2004091573A1
(en)
|
2003-03-04 |
2004-10-28 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
CA2525771A1
(en)
|
2003-05-14 |
2004-12-02 |
Teva Pharmaceutical Industries Ltd. |
Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
|
|
US20050147687A1
(en)
|
2003-07-18 |
2005-07-07 |
Julia Rashba-Step |
Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation
|
|
US20050142205A1
(en)
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
|
US20060276390A1
(en)
|
2003-07-31 |
2006-12-07 |
Yeda Research And Development Co. Ltd. |
Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
|
|
NZ546379A
(en)
|
2003-10-31 |
2010-04-30 |
Teva Pharma |
Nanoparticles for drug delivery
|
|
JP5456235B2
(ja)
|
2003-11-12 |
2014-03-26 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
神経変性疾患を治療するためのワクチン及び方法
|
|
WO2005070332A1
(en)
|
2004-01-12 |
2005-08-04 |
The Trustees Of The University Of Pennsylvania |
Long-term delivery formulations and methods of use thereof
|
|
RU2006134701A
(ru)
|
2004-03-01 |
2008-04-10 |
Пептиммьюн |
Способы и композиции для лечения аутоиммунных заболеваний
|
|
WO2005084377A2
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US7576051B2
(en)
|
2004-03-11 |
2009-08-18 |
Sanyo Chemical Industries, Ltd. |
Wound dressing for accelerating epidermal regeneration
|
|
CN101022728B
(zh)
|
2004-03-25 |
2012-08-08 |
詹森药业有限公司 |
咪唑化合物
|
|
EP2508194A1
(en)
|
2004-05-07 |
2012-10-10 |
Ares Trading S.A. |
Methods of treating disease with random copolymers
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
MY194883A
(en)
|
2004-06-04 |
2022-12-21 |
Genentech Inc |
Method for treating multiple sclerosis
|
|
WO2006012641A2
(en)
|
2004-07-30 |
2006-02-02 |
Oregon Health And Science University |
Methods for detecting and treating autoimmune disorders
|
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
US20090048181A1
(en)
|
2004-09-02 |
2009-02-19 |
Schipper Hyman M |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
DK1797109T3
(en)
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
|
DK1799703T3
(da)
|
2004-09-09 |
2010-04-19 |
Teva Pharma |
Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
|
|
DE602005016292D1
(de)
|
2004-10-29 |
2009-10-08 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
|
JP2008520717A
(ja)
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
CA2588908C
(en)
|
2004-11-29 |
2014-09-23 |
Yeda Research And Development Co. Ltd |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
|
JP2008528589A
(ja)
|
2005-02-02 |
2008-07-31 |
テバ ファーマシューティカル インダストリーズ リミティド |
水素化分解を用いてポリペプチド混合物を作成する方法
|
|
US20090130121A1
(en)
|
2005-02-02 |
2009-05-21 |
Yeda Research And Development Co., Ltd. |
Synthetic Peptide Copolymers for Treatment and Prevention of Cardiovascular Disorders
|
|
WO2006089066A1
(en)
|
2005-02-15 |
2006-08-24 |
Neuromolecular Pharmaceuticals, Inc. |
Combinations therapy for treatment of demyelinating conditions
|
|
ES2420404T3
(es)
|
2005-02-17 |
2013-08-23 |
Teva Pharmaceutical Industries Ltd. |
Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
WO2006116602A2
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
NZ564065A
(en)
|
2005-05-20 |
2011-03-31 |
Vertex Pharma |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
WO2007021970A2
(en)
|
2005-08-15 |
2007-02-22 |
Praecis Pharmaceuticals, Inc. |
Stable pharmaceutical formulations and methods of use thereof
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
US7517856B2
(en)
|
2005-10-11 |
2009-04-14 |
Ben-Gurion University Of The Negev Research And Development Authority |
Bioconjugates comprising sulfated polysaccharides and their uses
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
EP2007392A4
(en)
|
2006-02-28 |
2010-04-07 |
Elan Pharm Inc |
METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
|
|
CA3127202A1
(en)
|
2006-02-28 |
2007-09-07 |
Biogen Ma Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
EP2002258B1
(en)
|
2006-03-15 |
2017-09-27 |
The Brigham and Women's Hospital, Inc. |
Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
|
|
CN101479607B
(zh)
|
2006-04-28 |
2013-10-02 |
莫门塔制药股份有限公司 |
评估肽混合物的方法
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
ES2605154T3
(es)
|
2006-06-28 |
2017-03-13 |
Yeda Research And Development Company Limited |
Copolímero 1 para el tratamiento de la degeneración macular relacionada con la edad
|
|
JP5535623B2
(ja)
|
2006-06-30 |
2014-07-02 |
アッヴィ バイオテクノロジー リミテッド |
自動注射装置
|
|
WO2008006026A1
(en)
|
2006-07-05 |
2008-01-10 |
Momenta Pharmaceuticals, Inc. |
Improved process for the preparation of copolymer-1
|
|
CA2663589A1
(en)
|
2006-10-06 |
2008-05-22 |
Baxter International Inc. |
Microencapsules containing surface-modified microparticles and methods of forming and using the same
|
|
NZ577111A
(en)
|
2006-12-15 |
2012-05-25 |
Abbott Lab |
Novel oxadiazole compounds
|
|
WO2008075365A1
(en)
|
2006-12-20 |
2008-06-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions and methods for treatment of age related degeneration of the retina
|
|
EP3135282A1
(en)
|
2007-02-08 |
2017-03-01 |
Biogen MA Inc. |
Neuroprotection in demyelinating diseases
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
DK2187882T3
(da)
|
2007-07-11 |
2013-04-08 |
Medicinova Inc |
Behandling af progressiv neurodegenerativ sygdom med ibudilast
|
|
US8193147B2
(en)
|
2007-09-24 |
2012-06-05 |
Hadasit Medical Research Services & Development Ltd. |
Use of copolymer 1 for treatment of muscular dystrophy
|
|
EP2203051A4
(en)
|
2007-09-25 |
2011-09-07 |
Abbott Lab |
OCTAHYDROPENTAL COMPOUNDS AS CHEMOKIN RECEPTOR ANTAGONISTS
|
|
AU2008304313B2
(en)
|
2007-09-26 |
2013-01-10 |
Oregon Health & Science University |
Cyclic undecapeptides and derivatives as multiple sclerosis therapies
|
|
WO2009063459A2
(en)
|
2007-11-13 |
2009-05-22 |
Yeda Research And Development Co. Ltd |
Synthetic peptide copolymers for treatment of neurodevelopmental disorders
|
|
US20090149541A1
(en)
|
2007-11-28 |
2009-06-11 |
Yafit Stark |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
WO2010011879A2
(en)
|
2008-07-25 |
2010-01-28 |
The Johns Hopkins University |
Methods and compositions for treating and preventing autoimmune diseases
|
|
WO2010024908A1
(en)
|
2008-08-26 |
2010-03-04 |
Fibrogen, Inc. |
Methods for treatment of multiple sclerosis
|
|
AU2009291781A1
(en)
|
2008-09-10 |
2010-03-18 |
Acorda Therapeutics, Inc. |
Methods of using sustained release aminopyridine compositions
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
WO2010045265A1
(en)
|
2008-10-13 |
2010-04-22 |
Biovista, Inc. |
Compositions and methods for treating multiple sclerosis
|
|
CN102395275A
(zh)
|
2008-12-11 |
2012-03-28 |
拜欧维斯塔公司 |
用四环吡嗪并吲哚治疗多发性硬化症的方法
|
|
EP2398499B1
(en)
|
2009-02-18 |
2017-09-06 |
Eyeon Particle Sciences LLC |
Bi-functional co-polymer use for ophthalmic and other topical and local applications
|
|
EP2246048A1
(en)
|
2009-04-30 |
2010-11-03 |
Santhera Pharmaceuticals (Schweiz) AG |
Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
|
|
NZ577731A
(en)
|
2009-06-16 |
2010-08-27 |
Innate Therapeutics Ltd |
Compositions and methods for treatment of multiple sclerosis
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
PT2275086E
(pt)
|
2009-07-15 |
2012-05-18 |
Teva Pharma |
Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
|
|
KR20160038057A
(ko)
|
2009-08-20 |
2016-04-06 |
에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 |
글라티라머 아세테이트를 포함하는 약제
|
|
AU2013203367C1
(en)
|
2009-08-20 |
2018-01-18 |
Yeda Research & Development Co., Ltd |
Low frequency glatiramer acetate therapy
|
|
US8962676B2
(en)
|
2009-10-22 |
2015-02-24 |
University College Dublin, National University Of Ireland, Dublin |
Causal therapy of diseases or conditions associated with CNS or PNS demyelination
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
CN107661490B
(zh)
*
|
2010-01-04 |
2021-12-31 |
Mapi医药公司 |
包含格拉默或其药用盐的储药系统
|
|
US20110250206A1
(en)
|
2010-02-11 |
2011-10-13 |
Axtell Robert C |
Markers for determination of patient responsiveness
|
|
ME02317B
(me)
|
2010-02-12 |
2016-06-20 |
Biogen Ma Inc |
Neuroprotekcija kod demijelinizacijskih bolesti
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
EP2529757B1
(en)
*
|
2011-05-31 |
2014-01-08 |
Laboratorios Farmaceuticos Rovi, S.A. |
Paliperidone implant formulation
|
|
EP2598889A4
(en)
|
2010-07-29 |
2014-01-22 |
Reddys Lab Ltd Dr |
MOLECULAR WEIGHT MARKER FOR GLATIRAMERACETATE
|
|
AU2011291586A1
(en)
*
|
2010-08-20 |
2013-03-07 |
Cerulean Pharma Inc. |
Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
|
|
EP2627669B1
(en)
|
2010-10-11 |
2016-08-17 |
Teva Pharmaceutical Industries Ltd. |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
GB2485169A
(en)
|
2010-11-03 |
2012-05-09 |
Univ Jw Goethe Frankfurt Main |
(R)-flurbiprofen for use in the treatment of multiple sclerosis
|
|
EP2500072A1
(en)
|
2011-03-15 |
2012-09-19 |
LEK Pharmaceuticals d.d. |
A novel process of residual solvent removal
|
|
JP2014513289A
(ja)
|
2011-04-08 |
2014-05-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
IFNβに対する治療応答性を予測するバイオマーカーおよびその使用
|
|
RU2623161C2
(ru)
|
2011-04-15 |
2017-06-22 |
Компуджен Лтд. |
Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
|
|
WO2012143924A1
(en)
|
2011-04-21 |
2012-10-26 |
Mapi Pharma Ltd. |
Random pentapolymer for treatment of autoimmune diseases
|
|
WO2012154215A1
(en)
|
2011-05-04 |
2012-11-15 |
Cellular Technology, Ltd. |
Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
|
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
US8815511B2
(en)
|
2011-10-10 |
2014-08-26 |
Teva Pharmaceutical Industries, Ltd. |
Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
|
|
HK1206283A1
(en)
|
2012-03-12 |
2016-01-08 |
Medimmune, Llc |
Treatment of multiple sclerosis with anti-cd19 antibody
|
|
GB201208850D0
(en)
|
2012-05-18 |
2012-07-04 |
Alphaptose Gmbh |
Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
|
|
US9132138B2
(en)
|
2012-08-27 |
2015-09-15 |
Casi Pharmaceuticals, Inc. |
Method for the treatment of multiple sclerosis
|
|
AU2013329421A1
(en)
|
2012-10-09 |
2015-04-30 |
Biogen Ma Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
|
TW201420111A
(zh)
|
2012-10-10 |
2014-06-01 |
Teva Pharma |
對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記
|
|
CN105228651A
(zh)
|
2013-01-04 |
2016-01-06 |
泰华制药工业有限公司 |
表征醋酸格拉替雷相关的药品
|
|
BR112015016189A8
(pt)
|
2013-01-08 |
2019-10-22 |
Pathologica Llc |
usos de metilglioxal bis (guanilhidrazona) (mgbg), uso de metilglioxal bis (guanilhidrazona) (mgbg) e um agente e composição farmacêutica
|
|
CA2900503A1
(en)
|
2013-02-15 |
2014-08-21 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with laquinimod
|
|
EP2968559A4
(en)
|
2013-03-12 |
2016-11-02 |
Teva Pharma |
RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMERACETATE THERAPY
|
|
US20160040236A1
(en)
|
2013-03-15 |
2016-02-11 |
Biogen Ma Inc. |
Systems and methods for characterization of multiple sclerosis
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
|
US20160272707A1
(en)
|
2013-09-11 |
2016-09-22 |
Compugen Ltd. |
Vstm5 antibodies, and uses thereof for treatment of cancer, infectious diseases and immune related diseases
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
EP3119413B1
(en)
|
2014-03-17 |
2021-05-12 |
Mapi Pharma Limited |
Sublingual delivery of glatiramer acetate
|
|
WO2015168000A1
(en)
|
2014-04-28 |
2015-11-05 |
The Regents Of The University Of California |
Estrogen combination for treatment of multiple sclerosis
|
|
WO2016036721A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Estrogen receptor ligand treatment for neurodegenerative diseases
|
|
US10821117B2
(en)
|
2014-09-02 |
2020-11-03 |
The Regents Of The University Of California |
Estrogen therapy for brain gray matter atrophy and associated disability
|
|
US20170306402A1
(en)
|
2014-09-12 |
2017-10-26 |
Biogen Ma Inc. |
Systems and methods for characterization of multiple sclerosis
|
|
WO2016064997A1
(en)
|
2014-10-22 |
2016-04-28 |
The Regents Of The University Of California |
Compositions and methods for treating fatigue and depression
|
|
HK1246810A1
(zh)
|
2015-01-08 |
2018-09-14 |
Biogen Ma Inc. |
Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
|
|
US20160213633A1
(en)
|
2015-01-28 |
2016-07-28 |
Teva Pharmaceutical Industries, Ltd. |
Method of inducing anti-glatiramer acetate antibody response
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
US10406169B2
(en)
|
2015-03-30 |
2019-09-10 |
The Regents Of The University Of California |
Methods of monitoring estriol therapy
|
|
WO2016160830A1
(en)
|
2015-03-30 |
2016-10-06 |
The Regents Of The University Of California |
Methods of providing neuroprotective therapy
|
|
WO2018002930A1
(en)
|
2016-06-30 |
2018-01-04 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
JP7232752B2
(ja)
|
2016-08-28 |
2023-03-03 |
マピ ファーマ リミテッド |
酢酸グラチラマーを含有する微小粒子を調製する方法
|
|
US11167003B2
(en)
|
2017-03-26 |
2021-11-09 |
Mapi Pharma Ltd. |
Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
|
|
CN110709091A
(zh)
|
2017-05-15 |
2020-01-17 |
干细胞医药有限公司 |
使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
|